Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole

Drug Metabolism and Disposition

Volumn 27, Issue 5, 1999, Pages 596-599

  Gibbs, Megan A ^a   Kunze, Kent L ^a   Howald, William N ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; FLUCONAZOLE; KETOCONAZOLE;

ARTICLE; BINDING AFFINITY; DEPLETION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CLOTRIMAZOLE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0032904865     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Babany G, Larrey D and Pessayre D (1988) Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man, in Progress in Drug Metabolism (Gibson GG ed) vol 11, pp 61-98, Taylor & Francis, London.
2. Bourrie M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Davis DP, Kirk KL and Cohen LA (1982) New synthesis of 2-Nitroimidazoles. J Heterocycl Chem 19:253-256.
4. i values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
5. Guengerich FP (1997) Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43:7-35.
6. He MH, Kunze KL and Trager WF (1995) Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos 23:659-663.
7. Henderson PJF (1973) Steady-state enzyme kinetics with high affinity substrates or inhibitors. A statistical treatment of dose-response curves. Biochem J 135:101-107.
8. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior A-K, Dralle H, Hackbarth I and Sweing K-F (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-1324.
9. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
10. Morrison JF (1969) Kinetics of the reversible inhibition on enzyme-catalyzed reactions by tight binding inhibitors. Biochim Biophys Acta 185:269-286.
11. Obach RS (1996) The importance of nonspecific binding in in vivo matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047-1049.
12. Paine MF (1997) Intestinal versus hepatic CYP3A-dependent first-pass metabolism. [thesis]. Seattle, Washington: University of Washington, pp 207.
13. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of inter-and intra-intestinal differences in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
14. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons Inc., New York.
15. Sutton D, Butler A, Nadin L and Murray M (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 282:294-300.
16. Szedlacesek SE and Duggleby RG (1995) Kinetics of slow and tight-binding inhibitors, in Methods in Enzymology (Purich DL ed) vol 249, pp 144-180, Academic Press, New York.
17. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD and Carrithers RL Jr (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intra-individual hepatic P4503A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566.
18. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS and Shader RI (1996) Midazolam hydroxylation by liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791.
19. Voorman R, Maio S, Payne N, Zhao Z, Koeplinger K and Wang X (1998) Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287:381-388.
20. Webb JL (1963) Enzyme and Metabolic Inhibitors. Academic Press Inc., New York.
21. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-923.